-
1
-
-
20044382779
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004
-
Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629
-
(2005)
J Clin Oncol
, vol.23
, pp. 619-629
-
-
Winer, E.P.1
Hudis, C.2
Burstein, H.J.3
-
2
-
-
33947510501
-
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
-
Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
-
(2007)
J Clin Oncol
, vol.25
, pp. 486-492
-
-
Coates, A.S.1
Keshaviah, A.2
Thurlimann, B.3
-
3
-
-
33748692794
-
First mature analysis of the Intergroup Exemestane Study
-
Coombes R.C., Paridaens R., Jassem J., Van de Velde C.J., Delozier T., Jones S.E., et al. First mature analysis of the Intergroup Exemestane Study. J Clin Oncol 24 Part I (2006) 18S
-
(2006)
J Clin Oncol
, vol.24
, Issue.PART I
-
-
Coombes, R.C.1
Paridaens, R.2
Jassem, J.3
Van de Velde, C.J.4
Delozier, T.5
Jones, S.E.6
-
4
-
-
7444259675
-
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
-
Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
-
(2003)
N Engl J Med
, vol.349
, pp. 1793-1802
-
-
Goss, P.E.1
Ingle, J.N.2
Martino, S.3
-
5
-
-
23444446523
-
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
-
Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
-
(2005)
Lancet
, vol.366
, pp. 455-462
-
-
Jakesz, R.1
Jonat, W.2
Gnant, M.3
-
6
-
-
33644984327
-
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial n0032
-
Ingle J.N., Suman V.J., Rowland K.M., et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial n0032. J Clin Oncol 24 (2006) 1052-1056
-
(2006)
J Clin Oncol
, vol.24
, pp. 1052-1056
-
-
Ingle, J.N.1
Suman, V.J.2
Rowland, K.M.3
-
7
-
-
33846543806
-
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss group for clinical cancer research trial (SAKK 21/00)
-
Perey L., Paridaens R., Hawle H., et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss group for clinical cancer research trial (SAKK 21/00). Ann Oncol 18 (2007) 64-69
-
(2007)
Ann Oncol
, vol.18
, pp. 64-69
-
-
Perey, L.1
Paridaens, R.2
Hawle, H.3
-
8
-
-
43249130208
-
-
Chia S, Gradishar W, Mauriac L, et al. A Double-blind, randomized, placebo-controlled trial of fulvestrant compared with exemestane after prior non steroidal aromatase inhibitor therapy in post menopausal women with hormone receptor-positive advanced breast cancer: Results from EFECT. J Clin Oncol Published online March 3, 2008, 10.1200/JCO.2007.13.5822.
-
Chia S, Gradishar W, Mauriac L, et al. A Double-blind, randomized, placebo-controlled trial of fulvestrant compared with exemestane after prior non steroidal aromatase inhibitor therapy in post menopausal women with hormone receptor-positive advanced breast cancer: Results from EFECT. J Clin Oncol Published online March 3, 2008, 10.1200/JCO.2007.13.5822.
-
-
-
-
9
-
-
40949122145
-
Activity of fulvestrant in patients with visceral metastases: results from EFECT
-
abs 2126
-
Romieu G., Bines J., and Mauriac L. Activity of fulvestrant in patients with visceral metastases: results from EFECT. Eur J Cancer Suppl 5 (2007) 222 abs 2126
-
(2007)
Eur J Cancer Suppl
, vol.5
, pp. 222
-
-
Romieu, G.1
Bines, J.2
Mauriac, L.3
-
10
-
-
0000582426
-
Treatment of metastatic breast cancer
-
Harris J.R. (Ed), Lippincott Williams & Wilkins, Philadelphia
-
Ellis M.J., Hayes D.F., and Lippman M. Treatment of metastatic breast cancer. In: Harris J.R. (Ed). Diseases of the breast (2000), Lippincott Williams & Wilkins, Philadelphia 749-797
-
(2000)
Diseases of the breast
, pp. 749-797
-
-
Ellis, M.J.1
Hayes, D.F.2
Lippman, M.3
-
11
-
-
0034994856
-
Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast
-
Kuerer H.M., Buzdar A.U., and Singletary E. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol 77 (2001) 139-147
-
(2001)
J Surg Oncol
, vol.77
, pp. 139-147
-
-
Kuerer, H.M.1
Buzdar, A.U.2
Singletary, E.3
-
12
-
-
0038683988
-
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials
-
Robertson J.F., Osborne C.K., Howell A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98 (2003) 229-238
-
(2003)
Cancer
, vol.98
, pp. 229-238
-
-
Robertson, J.F.1
Osborne, C.K.2
Howell, A.3
-
13
-
-
22244449598
-
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials
-
Howell A., Pippen J., Elledge R.M., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104 (2005) 236-239
-
(2005)
Cancer
, vol.104
, pp. 236-239
-
-
Howell, A.1
Pippen, J.2
Elledge, R.M.3
-
14
-
-
27144494936
-
Fulvestrant ('Faslodex'): clinical experience from the compassionate use programme
-
Steger G.G., Gips M., Simon S.D., et al. Fulvestrant ('Faslodex'): clinical experience from the compassionate use programme. Cancer Treat Rev 31 Suppl. 2 (2005) S10-S16
-
(2005)
Cancer Treat Rev
, vol.31
, Issue.SUPPL. 2
-
-
Steger, G.G.1
Gips, M.2
Simon, S.D.3
-
15
-
-
33748110786
-
Intentional and non-intentional non-adherence to medication amongst breast cancer patients
-
Atkins L., and Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42 (2006) 2271-2276
-
(2006)
Eur J Cancer
, vol.42
, pp. 2271-2276
-
-
Atkins, L.1
Fallowfield, L.2
-
16
-
-
27144456229
-
Incidence of polypharmacy in patients with breast cancer
-
Robertson J.F.R. Incidence of polypharmacy in patients with breast cancer. Breast 14 Suppl. 1 (2005) S39
-
(2005)
Breast
, vol.14
, Issue.SUPPL. 1
-
-
Robertson, J.F.R.1
-
17
-
-
31544469565
-
Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer
-
Fallowfield L., Atkins L., Catt S., et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17 (2006) 205-210
-
(2006)
Ann Oncol
, vol.17
, pp. 205-210
-
-
Fallowfield, L.1
Atkins, L.2
Catt, S.3
-
18
-
-
11444251764
-
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
-
ATAC Trialists' Group
-
ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
-
(2005)
Lancet
, vol.365
, pp. 60-62
-
-
-
19
-
-
29544433211
-
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
-
Thurlimann B., Keshaviah A., Coates A., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
-
(2005)
N Engl J Med
, vol.353
, pp. 2747-2757
-
-
Thurlimann, B.1
Keshaviah, A.2
Coates, A.3
-
20
-
-
33846545851
-
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
-
Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
-
(2007)
Lancet
, vol.369
, pp. 559-570
-
-
Coombes, R.C.1
Kilburn, L.S.2
Snowdon, C.F.3
-
21
-
-
0038683988
-
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women-a prospective combined analysis of two multicenter trials
-
Robertson J.F., Osborne C.K., Howell A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women-a prospective combined analysis of two multicenter trials. Cancer 98 (2003) 229-238
-
(2003)
Cancer
, vol.98
, pp. 229-238
-
-
Robertson, J.F.1
Osborne, C.K.2
Howell, A.3
-
22
-
-
85074743634
-
Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant
-
Robertson J.F.R., Agrawal A., Hannon R.A., Cheung K.L., and Eastell R. Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant. Breast 16 (2007) S53
-
(2007)
Breast
, vol.16
-
-
Robertson, J.F.R.1
Agrawal, A.2
Hannon, R.A.3
Cheung, K.L.4
Eastell, R.5
-
23
-
-
0035884408
-
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer
-
Robertson J.F., Nicholson R.I., Bundred N.J., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61 (2001) 6739-6746
-
(2001)
Cancer Res
, vol.61
, pp. 6739-6746
-
-
Robertson, J.F.1
Nicholson, R.I.2
Bundred, N.J.3
-
24
-
-
0037102126
-
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial
-
Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20 (2002) 3386-3395
-
(2002)
J Clin Oncol
, vol.20
, pp. 3386-3395
-
-
Osborne, C.K.1
Pippen, J.2
Jones, S.E.3
-
25
-
-
0037102121
-
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
-
Howell A., Robertson J.F.R., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 (2002) 3396-3403
-
(2002)
J Clin Oncol
, vol.20
, pp. 3396-3403
-
-
Howell, A.1
Robertson, J.F.R.2
Quaresma Albano, J.3
-
26
-
-
34548241775
-
Fulvestrant (Faslodex) how to make a good drug better
-
Robertson J.F. Fulvestrant (Faslodex) how to make a good drug better. Oncologist 12 (2007) 774-784
-
(2007)
Oncologist
, vol.12
, pp. 774-784
-
-
Robertson, J.F.1
-
27
-
-
0042232592
-
Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation
-
Martin L.-A., Farmer I., Johnston S.R.D., et al. Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278 (2003) 30458-30468
-
(2003)
J Biol Chem
, vol.278
, pp. 30458-30468
-
-
Martin, L.-A.1
Farmer, I.2
Johnston, S.R.D.3
-
28
-
-
20444448539
-
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model
-
Jelovac D., Macedo L., Goloubeva O.G., Handratta V., and Brodie A.M. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 65 (2005) 5439-5444
-
(2005)
Cancer Res
, vol.65
, pp. 5439-5444
-
-
Jelovac, D.1
Macedo, L.2
Goloubeva, O.G.3
Handratta, V.4
Brodie, A.M.5
|